OTC:CC - Ocumetics Reports Encouraging One-Month Postoperative Results
(TheNewswire)
Calgary, Alberta – TheNewswire - October 8, 2025 -Ocumetics Technology Corp . (“Ocumetics” or the “Company”)(TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advancedophthalmic technology, is pleased to reportencouraging one-month safety and vision performance results for thefirst Group 1 patients that received the Ocumetics AccommodatingIntraocular Lens (the “Ocumetics Lens”).
“This again is a historic milestone for Ocumetics andfor ophthalmology as a whole,” said Dean Burns, President and CEO ofOcumetics Technology Corp. “The safety profile and visual outcomeswe’re seeing at this early stage are what we hoped for, and we areexcited to continue building momentum as the clinical trialprogresses. These early outcomes highlight the transformativepotential of the Ocumetics Lens and provide a strong foundation forcontinued clinical progress.”
“The early results are very exciting,” said Dr.Doyle Stulting, Chief Medical Officer of Ocumetics. “Afterone-month, initial patients are already achieving functional distancevision of 20/40 or better without glasses and are showing encouragingsigns of near vision performance with no complications. These resultsgive us confidence the outcomes will continue to improve in the monthsahead.”
“This moment is the culmination of decades ofresearch and innovation,” added Dr. Garth Webb, Chief Scientist andFounder of Ocumetics. “Our vision has always been to restorenatural, seamless vision across all distances. Seeing these earlyclinical results come to life is incredibly inspiring, and I believewe are only beginning to see the true potential of the OcumeticsAccommodating Intraocular Lens.”
Ocumetics emphasizes that while these early results arealready promising, continued improvement is expected over the comingmonths as patients adapt and the clinical program advances. TheCompany remains committed to its mission of offering patients clear,continuous vision without dependence on glasses or contactlenses.
The Company’s first-in-human clinical protocol wasstrategically designed to enroll three patient groups. The outcomesfor the one-month evaluation in each group are focused on thefollowing key areas:
Safety - determining the frequency of intraocular lensand surgery related adverse outcomes
Surgical technique - evaluating the surgical methods toeasily implant the Ocumetics Lens into the eye
Distance vision correction - assessing the OcumeticsLens’s ability to restore far vision
About Ocumetics
Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO)is a Canadian research and product development company that is dedicated to developing advanced visioncorrection solutions that enhance the quality of life for patients. Through innovative research and development, Ocumetics aims totransform the field of ophthalmology with state-of-the-art intraocularlenses and other vision-enhancing technologies.
Ocumetics is in the first-in-human early feasibilitystudy phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed an intraocular lens that fits within thenatural lens compartment of the eye, potentially to eliminate the needfor corrective lenses. It is designed to allow the eye’s naturalmuscle activity to shift focus from distance to near, providing clearvision at all distances without the help of glasses or contact lenses.
FOR FURTHER INFORMATION, PLEASECONTACT:
Dave Burwell
Director, Investor Relations
(403) 410-7907
Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to,statements with respect to the commencement, timing and scope of theresearch and development to be conducted by the Corporation mentionedabove. Forward-looking statements are necessarily based upon anumber of estimates and assumptions that, while considered reasonable,are subject to known and unknown risks, uncertainties, and otherfactors which may cause the actual results and future events to differmaterially from those expressed or implied by such forward-lookingstatements. Such factors include but are not limited to: operationalmatters, historical trends, current conditions and expected futuredevelopments, access to financing as well as other considerations thatare believed to be appropriate in the circumstances. There can be noassurance that such statements will prove to be accurate, as actualresults and future events could differ materially from thoseanticipated in such statements. Accordingly, readers should not placeundue reliance on forward-looking statements. The Corporationdisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise, except as required by law.
Copyright (c) 2025 TheNewswire - All rights reserved.